Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

摘要: BACKGROUND. We conducted a phase 2, multicenter, open-label study of erlotinib plus bevacizumab in patients with malignant pleural mesothelioma who had previously received 1 prior chemotherapy regimen. These agents have activity non–small cell lung cancer, but their role is unclear. The primary endpoint response rate. Secondary endpoints include time to progression, survival, and toxicity. METHODS. Eligible regimen were treated 150 mg per os daily 15 mg/kg administered intravenously on Day 21-day cycle. Treatment continued until disease progression or development significant toxicity. Tumor was assessed after every 2 cycles using established criteria from Byrne Nowak. RESULTS. Twenty-four eligible initiated therapy between February 2004 October 2006. There no complete partial responses, although 12 achieved stable for at least treatment. median 2.2 months (95% confidence interval [CI], 1.4 months-5.9 months). survival 5.8 CI, 2.8 months-10.1 most common toxicities rash diarrhea. treatment-related deaths, intracranial bleeding, hemoptysis. CONCLUSIONS. The combination tolerated reasonably well, there evidence radiographic response. This demonstrates the feasibility conducting trials failed first-line therapy. More therapeutic studies effective are needed these patients. Cancer 2008. © 2008 American Society.